While dual and triple agonists represent a promising area of pharmacologic innovation, their role in adolescent obesity management cannot be established without dedicated pediatric clinical trials
Barrea L, Verde L, Surez R, Frias-Toral E, Vsquez CA, Colao A, et al
Selectivity & Safety Profile: Ipamorelin is highly regarded in research for its "clean" profile, as it does not significantly increase prolactin, cortisol, or appetite-stimulating hormones, allowing for focused GH studies
The pipeline of GLP-1 drugs in development is robust, promising even more options for patients in the coming years
Fat dissolving injections are one of the most-asked-about treatments across our seven UK clinics, and the question we hear most often is some version of aqualyx vs lemon bottle, which one should I have? The two products are marketed in similar ways, for similar areas, at very different price points
Mant CT, Chen Y, Yan Z, et al